Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Stimulants linked to more severe erythromelalgia in Raynaud patients. A new study found that patients with both erythromelalgia and Raynaud phenomenon who used stimulants had significantly more body areas affected and more facial flushing. Nearly all stimulant users reported new or worsened symptoms after starting the drugs — and stopping them often helped.
Stimulants linked to more severe erythromelalgia in Raynaud patients
A retrospective study out of Mayo Clinic found a notable connection between stimulant use and worsened erythromelalgia in patients who also have Raynaud phenomenon (RP). Stimulant users had significantly more body areas affected by the painful burning-and-redness condition compared to non-users — and were far more likely to experience facial flushing and unprovoked episodes with no identifiable trigger.
Among stimulant users with available timeline data, 97% reported new or worsened symptoms after starting a stimulant. Of the eight patients who stopped using stimulants, five saw resolution or improvement of their erythromelalgia.
By the Numbers
Why it matters: Clinicians treating patients with erythromelalgia and RP should routinely ask about stimulant use — prescription or recreational. Discontinuing stimulants may meaningfully reduce symptoms and should be explored through shared decision-making.
